Impact of Therapeutic Osteopathy-hypnosis on Cancer Patients.
Condition(s) studied
Investigational drug(s) / intervention(s)
Osteopathy: An osteopathy session includes a health history chat, physical assessment, hands-on treatment, and aftercare advice.
Hypnosis: Hypnosis sessions consisted in deep relaxation and focused concentration, delivered by practitioners trained in the therapy.
Study summary
Osteopathy is recognized as a beneficial complementary approach for cancer patients. By addressing tissue mobility, circulation, and muscle tension, it helps improve physical comfort, reduce musculoskeletal pain, and foster better functional recovery. Several studies have shown that osteopathy can help reduce pain intensity and improve the quality of life for patients undergoing cancer treatment.
Combining hypnosis with osteopathy could thus optimize treatment outcomes by integrating a holistic approach that addresses both physical and psychological needs. The aim of this study is to evaluate the impact of combined osteopathy and hypnosis treatment compared to osteopathic treatment alone in cancer patients, particularly regarding pain with a strong emotional component.
Eligibility
Primary outcome measure(s)
- Pain and quality of life — 6 weeks
Change in pain and functional quality of life assessed between baseline (Day 0) and 6 weeks using the Brief Pain Inventory (BPI). • Calculation: The mean (average) of four items measuring pain in the last 24 hours or past week: worst pain, least pain, average pain, and current pain ("pain right now"). (Alternatively, a single item like "worst pain" can be evaluated on its own). • Scale Range: 0 to 10 (0 = "no pain", 10 = "pain as bad as you could imagine"). Cut-offs: 0 - 3: Mild pain, 4 - 6: Moderate pain, 7 - 10: Severe pain
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Institut Rafael | Levallois-Perret | Île-de-France Region | Recruiting |
More Institut Rafael trials in France
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07860476 on ClinicalTrials.gov ↗ ← All trials in France